The potential agreement with the commission for 80 million doses also provides an option for European Union member states to purchase an additional 80 million doses for a total of up to 160 million doses. Discussions are underway to ensure that member states will have access to the vaccine.

The phase III study of mRNA-1273, a prefusion-stabilized spike protein mRNA vaccine against SARS-CoV-2, began on July 27 and is currently enrolling a target 30,000 participants by September.

Moderna is scaling up global manufacturing to be able to deliver approximately 500 million doses per year and possibly up to 1 billion doses per year beginning in 2021. In Europe, Moderna is partnering with Lonza in Switzerland and Rovi in Spain for manufacturing and fill-finish outside of the U.S.

U.S. to pay $1.5B for Moderna's COVID-19 vaccine
The U.S. government awarded a maximum $1.525 billion contract to Moderna to secure 100 million doses of its messenger RNA COVID-19 vaccine.

Amazon powers Moderna's digital biotech platform
Amazon Web Services is providing cloud, analytics, and machine-learning services to Moderna for its messenger RNA platform and manufacturing facility.

Animal study turns in positive results for Moderna-NIH COVID-19 vaccine
Moderna's COVID-19 vaccine candidate, messenger RNA (mRNA)-1273, has been shown to induce immune responses and control upper and lower respiratory tract...

Moderna begins phase III testing of COVID-19 vaccine
Moderna has begun a phase III clinical trial evaluating its messenger RNA (mRNA)-1273 COVID-19 vaccine candidate. The trial is expected to enroll approximately...

Moderna reports positive results in COVID-19 vaccine trial
Moderna is reporting positive results with a COVID-19 vaccine candidate it is developing. The candidate, messenger RNA (mRNA)-1273, was safe and triggered...